• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The combination of TP53INP1, TP53INP2 and AXIN2: potential biomarkers in papillary thyroid carcinoma.

作者信息

He Mengzi, Zhao Yinlong, Yi Heqing, Sun Hui, Liu Xiaodong, Ma Shumei

机构信息

Key Laboratory of Radiobiology (Ministry of Health), School of Public Health, Jilin University, 1163 Xinmin Street, Changchun, 130021, Jilin, China.

出版信息

Endocrine. 2015 Mar;48(2):712-7. doi: 10.1007/s12020-014-0341-8. Epub 2014 Aug 9.

DOI:10.1007/s12020-014-0341-8
PMID:25104271
Abstract
摘要

相似文献

1
The combination of TP53INP1, TP53INP2 and AXIN2: potential biomarkers in papillary thyroid carcinoma.TP53INP1、TP53INP2和AXIN2的组合：甲状腺乳头状癌中的潜在生物标志物
Endocrine. 2015 Mar;48(2):712-7. doi: 10.1007/s12020-014-0341-8. Epub 2014 Aug 9.
2
The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.将miRNA和mRNA联合用作诊断甲状腺乳头状癌的生物标志物。
Int J Mol Med. 2015 Oct;36(4):1097-103. doi: 10.3892/ijmm.2015.2305. Epub 2015 Aug 5.
3
Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma.血清钙卫蛋白：一种用于甲状腺乳头状癌的新型潜在生物标志物。
Tumour Biol. 2015 Sep;36(10):7549-56. doi: 10.1007/s13277-015-3468-1. Epub 2015 Apr 29.
4
Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.微小RNA在甲状腺乳头状癌中的表达及其与甲状腺乳头状癌临床特征的关联。
Cancer Biomark. 2017;18(1):87-94. doi: 10.3233/CBM-161723.
5
Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.比较血清蛋白质组学分析确定afamin为非131I摄取性肺转移的甲状腺乳头状癌患者中下调的蛋白质。
Nucl Med Commun. 2013 Dec;34(12):1196-203. doi: 10.1097/MNM.0000000000000001.
6
Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas.平均血小板体积可能是甲状腺乳头状癌的一种潜在生物标志物。
Asian Pac J Cancer Prev. 2015;16(7):2671-4. doi: 10.7314/apjcp.2015.16.7.2671.
7
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.甲状腺乳头状癌患者循环BRAF（V600E）的检测
J Mol Diagn. 2016 Jan;18(1):100-8. doi: 10.1016/j.jmoldx.2015.08.003. Epub 2015 Nov 26.
8
Hashimoto's thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value?桥本甲状腺炎与甲状腺乳头状癌。细胞角蛋白19和P63蛋白有诊断价值吗？
Hell J Nucl Med. 2016 Sep-Dec;19(3):250-253. doi: 10.1967/s002449910408. Epub 2016 Nov 8.
9
[Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].[微小RNA-221和白细胞介素-17在甲状腺乳头状癌中的表达及其与临床病理特征的相关性]
Zhonghua Bing Li Xue Za Zhi. 2017 Mar 8;46(3):160-165. doi: 10.3760/cma.j.issn.0529-5807.2017.03.004.
10
Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.红细胞沉降率和C反应蛋白在甲状腺乳头状癌和结节性甲状腺肿中的不同表达
Clin Lab. 2015;61(7):793-9. doi: 10.7754/clin.lab.2015.150127.

引用本文的文献

1
Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomization analysis.基于转录组数据和孟德尔随机化分析探索膀胱癌免疫相关基因及潜在治疗靶点
Front Immunol. 2025 Jul 18;16:1607098. doi: 10.3389/fimmu.2025.1607098. eCollection 2025.
2
Investigation of common genetic risk factors between thyroid traits and breast cancer.甲状腺特征与乳腺癌常见遗传风险因素的研究。
Hum Mol Genet. 2023 Dec 12;33(1):38-47. doi: 10.1093/hmg/ddad159.
3
An Autophagy-Related Gene Signature can Better Predict Prognosis and Resistance in Diffuse Large B-Cell Lymphoma.

本文引用的文献

1
Thyroid fine-needle aspiration: the relevance of BRAF mutation testing.甲状腺细针穿刺活检：BRAF 突变检测的相关性
Endocrine. 2014 Nov;47(2):351-3. doi: 10.1007/s12020-014-0222-1. Epub 2014 Mar 4.
2
Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.用于准确检测良性前列腺增生患者中前列腺癌的潜在尿液蛋白生物标志物候选物。
J Cancer. 2014 Jan 5;5(2):103-14. doi: 10.7150/jca.6890. eCollection 2014.
3
Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.
一种自噬相关基因特征能更好地预测弥漫性大B细胞淋巴瘤的预后和耐药性。
Front Genet. 2022 Jun 30;13:862179. doi: 10.3389/fgene.2022.862179. eCollection 2022.
4
Investigation of the Presence of Integrin Alpha-3 and Beta-1 Receptors on Tumor Tissue, Metastatic Lymph Node and Normal Tissue in Thyroid Cancer.甲状腺癌肿瘤组织、转移淋巴结及正常组织中整合素α-3和β-1受体表达情况的研究
Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):75-81. doi: 10.4274/mirt.galenos.2021.71501.
5
Evaluation of the mRNA expression levels of integrins α3, α5, β1 and β6 as tumor biomarkers of oral squamous cell carcinoma.整合素α3、α5、β1和β6作为口腔鳞状细胞癌肿瘤生物标志物的mRNA表达水平评估。
Oncol Lett. 2018 Oct;16(4):4773-4781. doi: 10.3892/ol.2018.9168. Epub 2018 Jul 18.
6
MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.miR-34a：肾细胞癌标志性特征的关键调节因子。
Oxid Med Cell Longev. 2017;2017:3269379. doi: 10.1155/2017/3269379. Epub 2017 Sep 20.
7
Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.甲状腺乳头状癌中关键微小RNA及其靶标的表达谱：来自癌症基因组图谱的分析
Onco Targets Ther. 2015 Aug 26;8:2271-7. doi: 10.2147/OTT.S85753. eCollection 2015.
即使甲状腺结节没有显示可疑的超声特征，额外的BRAF突变分析对于仅具有“可疑恶性”细胞学特征的甲状腺结节可能具有额外的诊断价值。
Endocrine. 2014 Sep;47(1):283-9. doi: 10.1007/s12020-013-0150-5. Epub 2014 Jan 23.
4
BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?甲状腺乳头状癌中的BRAF突变评估：我们准备好将其应用于临床实践了吗？
Endocrine. 2014 Apr;45(3):341-3. doi: 10.1007/s12020-013-0139-0. Epub 2013 Dec 24.
5
Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes.鉴定整合素 α3 作为细胞上皮-间充质转化和具有侵袭表型的癌细胞的分子标志物。
Cancer Sci. 2013 Sep;104(9):1189-97. doi: 10.1111/cas.12220. Epub 2013 Jul 20.
6
BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.通过焦磷酸测序法对合并桥本甲状腺炎的甲状腺结节细针穿刺样本进行BRAF（V600E）评估是一种可靠的检测方法。
Endocrine. 2014 Mar;45(2):249-55. doi: 10.1007/s12020-013-9994-y. Epub 2013 Jun 18.
7
Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma.甲状腺乳头状癌中 microRNAs 及其靶基因的表达谱。
Oncol Rep. 2013 Apr;29(4):1415-20. doi: 10.3892/or.2013.2263. Epub 2013 Jan 31.
8
BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.BRAF (V600E) 与甲状腺乳头癌细胞质中 p27kip1 的定位和细胞角蛋白 19 的高表达相关。
Endocrine. 2013 Aug;44(1):165-71. doi: 10.1007/s12020-012-9843-4. Epub 2012 Dec 1.
9
Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity.经典 Wnt 抑制因子 Axin2 促进结肠癌致癌活性。
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11312-7. doi: 10.1073/pnas.1203015109. Epub 2012 Jun 27.
10
Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?抑癌基因 p53 诱导核蛋白 1（TP53INP1）在甲状腺髓样癌中的表达：手术范围的最佳选择的分子指导？
World J Surg. 2010 Apr;34(4):830-5. doi: 10.1007/s00268-010-0395-6.